To the Editor:Accumulating evidence has shown that the preclinical stage of Alzheimer’s disease(AD)(i.e.,asymptomatic amyloidosis)lasts for decades before the onset of cognitive symptoms,providing a large window for ...To the Editor:Accumulating evidence has shown that the preclinical stage of Alzheimer’s disease(AD)(i.e.,asymptomatic amyloidosis)lasts for decades before the onset of cognitive symptoms,providing a large window for early intervention.Amyloid pathology,the earliest pathological change associated with AD,can be detected in vivo with cerebrospinal fluid(CSF)analysis or positron emission tomography(PET),and its presence is necessary for the diagnosis of preclinical AD(pre-AD).However,both PET scans and CSF analyses are expensive,hampering their use in large-scale screening.Thus,blood-based biomarkers are desirable alternatives,as they are cost-effective and not invasive.展开更多
基金supported by grants from the National Natural Science Foundation of China(Nos.82020108013 and 82001773)National Key Research and Development Program of China(No.2022YFC24069004)+1 种基金Beijing Brain Initiative from Beijing Municipal Science&Technology Commission(No.Z201100005520018)STI2030-Major Projects(No.2022ZD0211800)
文摘To the Editor:Accumulating evidence has shown that the preclinical stage of Alzheimer’s disease(AD)(i.e.,asymptomatic amyloidosis)lasts for decades before the onset of cognitive symptoms,providing a large window for early intervention.Amyloid pathology,the earliest pathological change associated with AD,can be detected in vivo with cerebrospinal fluid(CSF)analysis or positron emission tomography(PET),and its presence is necessary for the diagnosis of preclinical AD(pre-AD).However,both PET scans and CSF analyses are expensive,hampering their use in large-scale screening.Thus,blood-based biomarkers are desirable alternatives,as they are cost-effective and not invasive.
